TSX open
Loading markets…

Advertisement

Stocks

Why Telo Genomics Corp stock is plummeting today

By Wealth Awesome -

This move is archived. Current quotes and coverage live on the stock page.

Stocks & ETFs:TELO.V

Follow TELO

Photos provided by Pexels

Telo Genomics Corp's stock has taken a significant hit, dropping 12.50% in today's trading session.

Investors in Telo Genomics Corp (TELO.V) are feeling the pinch today as the stock plummets to CA$0.04, marking a notable decline of 12.50%. With a market cap of just over CA$4 million, this drop raises concerns about the company's stability and future prospects.

Advertisement

Telo Genomics Corp

TELO.V

Full stock page →

TELO.V

Telo Genomics Corp

Source:WealthAwesomeWealthAwesome
↑ $0.01 (11.11%)
120 day period
$0.04$0.05$0.07Mar 4Jun 1Oct 6

Market cap

$5.02M

52W high

$0.10

52W low

$0.03

1W change

+42.86%

Beta

0.11

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on TELO's historical volatility

HistoricalForecast68%95%
C$0.00C$0.08C$0.15C$0.23C$0.30C$0.37TodayApr 16Jun 22Oct 6Nov 18Jan 1Feb 13

30-Day Vol

180.7%

Annualized

90-Day Vol

142.9%

Annualized

Trend (90d)

-50.0%

Annualized drift

90d Mean

C$0.04

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$0.05C$0.03 – C$0.09
60 trading daysC$0.04C$0.02 – C$0.11
90 trading daysC$0.04C$0.01 – C$0.12

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Advertisement

Investor takeaway: The sharp decline in Telo Genomics' stock price highlights the volatility often associated with small-cap biotech firms, particularly in the absence of significant news or developments.

Telo Genomics Corp down 12.50% in one trading day.

With a market cap of CA$4,017,219, Telo Genomics remains a small player in the biotech sector, making it susceptible to significant price swings.

Bull case

Despite today's downturn, Telo Genomics is making progress in expanding its operations and forming partnerships, which could set the stage for future growth.

Bear case

The lack of recent news or positive developments raises concerns that there may be underlying issues affecting investor confidence in Telo Genomics.

Market Reaction

Advertisement

Today's 12.50% decline in Telo Genomics' stock is a stark reminder of the volatility that can plague small-cap biotech companies. Investors are left questioning the company's future as it faces challenges in gaining traction in a competitive industry.

Company Background

Telo Genomics Corp focuses on innovative diagnostic technologies, but with a market cap of just over CA$4 million, its financial health is under scrutiny. The company has recently relocated its laboratories to a larger facility in Toronto, which could be a positive sign for future growth, but investor sentiment remains cautious.

Looking Ahead

As Telo Genomics navigates its current challenges, investors should keep an eye on upcoming announcements and developments that could influence stock performance. The biotech sector is known for rapid changes, and any positive news could quickly shift the narrative.


Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: June 30, 2026
Last Updated: June 30, 2026

Core portfolio

Awesome Portfolio™

14.8% a year since 2017, against 9.7% for the S&P/TSX Composite. Ten stocks, easy to manage. We update it once a month.

Annualized

+14.8%

Awesome Portfolio™

+9.7%

S&P/TSX

+5.0 pp better a year

Total return

+254%

Awesome Portfolio™

+134%

S&P/TSX

+119 pp better than the TSX

2017-07-31 to 2026-09-29, dividends reinvested, before fees and tax.

Awesome Portfolio™S&P/TSX CompositeCumulative return · 2017-07-31–2026-09-29
-11.7%42.5%96.7%150.9%205.1%259.3%Jul 17Oct 19Feb 22Jun 24Sep 26

Sponsored links

Advertisement